User:Mr. Ibrahem/Andexanet alfa

Andexanet alfa, sold under the trade name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding. Evidence of benefit is not definitive as of 2021. It has not been found to be useful for other factor Xa inhibitors. It is given by injection into a vein.

Common side effects include pneumonia, urinary tract infection, feeling hot, and shortness of breath. Severe side effects may include blood clots, heart attacks, strokes, or cardiac arrest. It works by binding to rivaroxaban and apixaban.

Andexanet alfa was approved for medical use in the United States in 2018. It was developed by Portola Pharmaceuticals. The typical cost of using the medications per person is 25,000 to 50,000 USD in the United States as of 2019. In the United Kingdom it costs the NHS about £15,000 as of 2020. It is not available in Canada as of 2021.